Webinar recording: Adaptive Platform Trial Virtual Clinic – Session 5

Presented by Prof Dan Siskind – SWiMS – Schizophrenia, Weight, Metformin and Semaglutide

Antipsychotics are the mainstay of treatment for schizophrenia. However, antipsychotics are linked with obesity and diabetes, which increases the risk of heart disease. Preliminary research suggests the diabetes drugs semaglutide and metformin can reduce antipsychotic-related obesity. The team will undertake a national clinical trial to establish the role of semaglutide and metformin in reducing weight among obese people taking antipsychotics.